穿心莲内酯联合氟康唑抗耐药白假丝酵母菌作用机制研究

目的探讨穿心莲内酯联合氟康唑抗耐药白假丝酵母菌作用及其机制。方法采用微量稀释法检测穿心莲内酯（AG）及联合氟康唑（FLC）对耐药白假丝酵母菌的MIC;采用罗丹明6G（Rh6G）检测AG对耐药白假丝酵母菌CDR外排功能的影响;利用罗丹明123评估AG对耐药白假丝酵母菌MDR外排功能的影响：采用二氢罗丹明检测AG单用及联合FLC对耐药白假丝酵母菌活性氧（ROS）的影响;采用实时荧光定量PCR（qRT—PCR）检测AG联合FLC对耐药白假丝酵母菌外排泵相关基因CDR1、CDR2和MDR1表达的影响。结果AG联合FLC抗耐药白假丝酵母菌呈相加作用;AG对CDR外排功能无影响;AG可抑制MDR外排功能;AG联合FLC能显著提高耐药白假丝酵母菌细胞ROS水平;AG与FLC联合作用于耐药白假丝酵母菌可下调CDR1和MDR1的表达量,上调CDR2的表达量。结论AG联合FLC抗耐药白假丝酵母菌具有相加作用,其机制可能与抑制外排泵及相关基因表达,提高胞内ROS水平有关。     

白假丝酵母菌耐药与抗氰呼吸的相关性研究

目的探讨白假丝酵母菌的耐药情况及其与抗氰呼吸的相关性。方法用真菌药敏测定试剂盒测定从临床分离出来的37株白假丝酵母菌的耐药性,并从中选出5株耐药菌和5株敏感菌进行抗氰呼吸的研究。结果白假丝酵母菌对益康唑的耐药率最高,达54.1%,耐药白假丝酵母菌的抗氰呼吸速率均值为(17.56±6.75)nmol/(min.A620),敏感白假丝酵母菌的抗氰呼吸速率均值为(7.99±5.80)nmol/(min.A620),耐药白假丝酵母菌的抗氰呼吸速率明显升高,且耐药菌株抗氰呼吸速率占总呼吸的比例明显高于敏感菌株(P0.05),差异具有显著性。结论兰州市区白假丝酵母菌对益康唑耐药性较高,且白假丝酵母菌的耐药与抗氰呼吸途径相关。     

氟康唑体外诱导白假丝酵母菌耐药基因表达的研究

目的 对白假丝酵母菌耐药机制进行研究.方法 将临床分离对氟康唑敏感的白假丝酵母菌种,经体外诱导产生耐药.半定量PCR检测敏感株、耐药株、回复敏感株多药耐药基因CDR1、CDR2、MDR1和转录调控因子TAC1编码基因表达水平的变化,并对TAC1编码基因进行测序.结果 与敏感株和回复敏感株比较,耐药株CDR1、CDR2相对表达量增高,发现1株TAC1 N977D氨基酸置换.结论 氟康唑体外诱导白假丝酵母菌产生耐药的机制与CDR1、CDR2表达相关.TAC1基因突变在诱导耐药中的机制有待进一步研究.     

阴道白假丝酵母菌水解酶的研究进展

外阴阴道白假丝酵母菌病是常见的妇产科感染性疾病,对其致病微生物白假丝酵母菌的研究方向已从大范围的筛查病因过渡到小范围的深入研究,本文系统综述了近年来对白假丝酵母菌水解酶的研究发现和前沿进展。     

白假丝酵母菌滞留菌形成相关机制的研究进展

白假丝酵母菌属于临床侵袭性条件致病菌,可引起从浅表黏膜到危及生命的全身感染性疾病,其形成的生物膜是为生物膜内细胞提供结构支架和保护模式的结构化菌体群落,其产生的滞留菌是一种随机且对抗真菌药物高度耐受的细胞亚群。由于生物膜与滞留菌两种因素的存在,致使临床治疗侵袭性真菌感染时面临极大挑战,因此,研究白假丝酵母菌滞留菌形成机制对目前临床治疗侵袭性真菌感染具有重要意义。本文对白假丝酵母滞留菌形成的主要调控因素(生物膜的形成、氧化应激反应、蛋白酶系统、TOR-RAS-CAMP-PKA信号转导途径和菌种自身因素),以及滞留菌与临床疾病的相关性进行综述。     

白假丝酵母菌生物膜的研究进展

随着医疗水平的不断发展,越来越多的医疗操作、医疗设备和药物可能导致人体正常的微生物平衡被打破,使得机会致病菌白假丝酵母菌的感染呈现逐年上升的趋势。白假丝酵母菌在宿主或医疗器械表面形成生物膜的能力是一个十分关键的毒力因素。生物膜可以帮助白假丝酵母菌成功逃避宿主免疫并产生较强的耐药性,从而导致难治性真菌感染。本文从白假丝酵母菌生物膜的形成过程、生物膜相关的主要基因和影响生物膜毒力的因素3个方面介绍近年来的研究进展,为进一步研究白假丝酵母菌生物膜的形成机制提供参考。     

白假丝酵母菌体外生物膜药敏性不同检测方法的比较

目的比较不同的方法对白假丝酵母菌体外生物膜药敏性检测的差异。方法分别采用菌落计数法(CFU)、AlamarBlue试剂法、XTT减低法、MTT法对白假丝酵母菌体外48h成熟生物膜的药敏性进行检测,并将AlamarBlue试剂法、XTT减低法、MTT法与CFU法进行比较,观察其相关性及差异性。结果 AlamarBlue试剂法、XTT减低法、MTT法与CFU法都有较高的相关性,相关系数分别为r=0.969、r=0.971、r=0.982(P0.01);与CFU法的差异分别为(0.093±0.127)、(0.054±0.113)、(0.013±0.066),其差异无统计学意义(P0.05)。结论 AlamarBlue试剂法、XTT减低法、MTT法均可替代CFU法对白假丝酵母菌生物膜进行药敏检测。MTT法与CFU法的相关性最大,差异性最小;AlamarBlue试剂作为一种新的试剂,操作简单,对细胞及人类无毒害,更加适合高通量检测。     

白假丝酵母菌毒力相关的RAPD条带的克隆及其生物信息学分析

[目的]研究与白假丝念珠菌毒力相关的RAPD电泳条带的基因信息,明确这些条带是否来源于已知的毒力调控基因。[方法]通过对相关的白假丝酵母菌重新进行RAPD-PCR,切胶回收,以回收的DNA作为模板进行大量扩增,构建TA克隆,送测序。将获得的DNA信息登录Gen Bank数据库进行比对,寻找与包含这些条带信息的蛋白质。查阅文献,进行生物信息学分析,明确条带的基因信息与已发现的白假丝酵母菌调控基因之间的关系。[结果]白假丝酵母菌RAPD的450 bp条带为Abp1p(ABP1)蛋白的基因片段。[结论]Abp1p(ABP1)基因的过表达可能与下调磷脂酶表达有关,但具体机制有待进一步研究。     

呼吸道感染中白假丝酵母菌的致病性与细胞外水解酶关系

将84株呼吸道分离的白假丝酵母菌分为致病组和非致病组,采用卵黄培养基法检测细胞外磷脂酶的活力,用牛血清白蛋白琼脂培养基法检法分泌型天冬氨酸蛋白酶的活力,并用RT-PCR的方法检测这2种酶相关基因PLB1和SAP2的表达情况,分析其组间差别,结果表明致病组菌株的分泌型天冬氨酸蛋白酶的活力要高于非致病组(P=0.034<0.05),细胞外磷脂酶活力二组未见差别,致病组的PLB1和SAP2基因的表达均高于非致病组(P<0.05),PLB1和SAP2的表达存在着明显的正相关(r=0.776,P<0.01),提示分泌型天冬氨酸蛋白酶是呼吸道白假丝酵母菌重要的毒力因子,PLB1和SAP2的表达上调可能影响菌株的毒力,这2个基因的表达量有正相关的关系。     

应用流式细胞术对白假丝酵母菌耐药机制的研究

目的 探讨流式细胞术研究白假丝酵母菌耐药机制的可行性.方法 临床分离对氟康唑敏感的白假丝酵母菌种,经体外诱导产生耐药.应用荧光染料PI(碘化丙啶)和罗丹明123染色,通过流式细胞术检测敏感株、耐药株、回复敏感株的细胞周期和药物外排活性.结果 与敏感株和回复敏感株比较,耐药株增殖活性明显下降,但是药物外排活性显著增强.结论 应用氟康唑能够体外诱导白假丝酵母菌产生耐药.流式细胞术应用于白假丝酵母菌增殖活性和药物外排活性研究是可行的.     

白色念珠菌氟康唑耐药相关基因的差异显示研究

采用差异显示PCR技术 (DifferentialDisplay PCR ,DD PCR)寻找白色念珠菌的氟康唑耐药相关基因。体外用含氟康唑的酵母培养基 (YEPD)诱导培养临床白色念珠菌氟康唑敏感株 4 35 (对咪康唑耐药 ) ,诱导 80d后得到氟康唑耐药子代 4 35 2 (MIC =1 2 8μg mL)。DD PCR比较 4 35 2、4 35分别在含氟康唑、不含药的YEPD液基中的基因表达 ,找到 3个明显差异片段 ,分别与数据库中白色念珠菌的醇脱氢酶基因ADH1、多药耐药基因CDR1及拓扑异构酶基因TOP2有高度同源性。半定量RT PCR中证实了ADH1、CDR1在氟康唑耐药株中的差异表达 ;对已知氟康唑耐药基因MDR1作半定量RT PCR时发现MDR1在氟康唑耐药株 4 35 2中无表达 ,而在氟康唑敏感株 4 35中有表达。结果表明 ,ADH1、CDR1基因的高表达与白色念珠菌氟康唑耐药性形成相关 ,ADH1可能是新的耐药基因 ;MDR1的表达可能在氟康唑敏感株或其它唑类耐药株中也存在     

白念珠菌基因分型的相关研究

白色念珠菌定植于大多数人群的口腔中,在一定条件下可成为优势菌种而导致感染。基因分型是近年来白念分子生物学研究中的一个热点,随着医学科学技术的发展,由于深部真菌感染比例不断增加,分子生物学方法已经越来越广泛的应用于临床真菌病的研究中,从而为控制白念感染及为早期诊断、治疗提供基础。本文综述了限制性片段长度多态性、随机扩增多态性DNA分析、ITS区域序列分析等分子生物学技术在白念珠菌基因分型方面的相关研究,比较了它们的优缺点,并且讨论了将基因分型研究应用于临床诊断、治疗及开发新型抗真菌药物的发展趋势和广阔前景。认为目前更倾向于多种分型方法联合应用,并借助计算机软件进行分析,但是仍需进一步探索。     

Antifungal drug resistance pattern of Candida. spp isolated from vaginitis in Ilam-Iran during 2013-2014

Vaginal Candidiasis is the most common and important opportunistic fungal infection in women. By increasing use of antifungal drugs in recent years, it has caused drug resistance. This study aims to evaluate antifungal drugs susceptibility of Candida. spp isolated of women with vaginitis from Ilam-Iran during 2013-2014. samples were collected and cultured from 385 women with vaginitis, then Candida.spp was diagnosed by standard method. Antifungal drug susceptibility test for nystatin 100 unit/disk, fluconazole 10µg/disk, itraconazole 10µg/disk, ketoconazole 10µg/disk, amphotericinB 20µg/disk, clotrimazole 10µg/disk, posaconazole 5µg/disk, and voriconazole 1µg/disk were carried out by M44-A method(CLSI). From all culture positive samples, 150 isolates were Candida albicans and 89 isolates were non-albicans. The resistance to fluconazole, itraconazole, ketoconazole, clotrimazole, voriconazole, posaconazole, nystatin and amphotericin B was 76%, 62%, 72%, 55%, 6%, 7%, 1% and 0%. The highest resistance was seen for fluconazole , itraconazole, and the highest susceptible was seen for nystatin and amphotericin B. These results indicate nystatin and amphotericin B can be used as the first line for empirical therapy of vaginal candidiasis in the district.     

Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug

Abstract Mucosal candidosis is an almost inevitable consequence of AIDS. Resistance to fluconazole therapy associated with enhanced tolerance, detectable in microbiological estimation of sensitivity, occurs in up to 10% of cases with late-stage AIDS. We report here our biochemical analysis of the basis of resistance in a study of two susceptible and two resistant isolates. Resistance was not associated with a change in the target enzyme sterol 14α-demethylase, as indicated by equivalent levels of fluconazole inhibition of activity in extracts from all four isolates, or by mutations in sterol Δ ^5,6 desaturase as previously observed in Saccharomyces cereuisiae and Ustilago maydis . Reduced cellular content of fluconazole in the resistant isolates of between six to ten-fold was observed which could account for their resistant phenotype.     

Antifungal Activity of Schinifoline Against Candida Albicans in Caenorhabditis Elegans

Zanthoxylum schinifolium has been used as spices and traditional medicine in China for hundreds of years. A variety of active substances have been isolated from Zanthoxylum schinifolium using biological and chemical techniques. Among these substances, the effect of schinifoline has gradually attracted much attention. Candida albicans is one of the most common pathogens isolated from the gastrointestinal tract, vagina, and mouth in healthy individuals. In a healthy population, there are various mechanisms in host, such as the microbial flora, the epithelial barriers, and the innate immune system, that can control the presence of Candida albicans. However, when host immunity is compromised, an invasive fungal infection is more likely to occur. In this study, we explored the antifungal activity of schinifoline against Candida albicans in Caenorhabditis elegans. To determine the optimal concentration of schinifoline, we investigated the lifespan, defecation cycle and locomotion behavior of Caenorhabditis elegans after treatment with schinifoline. In addition, we examined colony formation in the intestine of Caenorhabditis elegans after Candida albicans infection. The results indicated that 100 and 200 mg/L of schinifoline could prolonged the lifespan, shorten the defecation cycle and increased the locomotion behavior of Caenorhabditis elegans, with 100 mg/L of schinifoline being the optimal concentration. Moreover, 100 mg/L of schinifoline increased the lifespan of Caenorhabditis elegans after infection and inhibited the colony formation of Candida albicans in Caenorhabditis elegans intestine. Therefore, we concluded that schinifoline exhibits anti-fungal effects and its potential use as natural drugs should be further explored in future studies.     

米诺环素对临床几种常见假丝酵母菌体外药敏的初步探究

探究米诺环素在体外对常见酵母菌的药敏特点。采用Rosco纸片扩散法对168株常见的几种假丝酵母菌进行米诺环素的药敏试验。米诺环素有抑菌环的比率:白假丝酵母菌41%,光滑假丝酵母菌1.2%,热带假丝酵母菌和克柔假丝酵母菌没有抑菌环。在常见几种酵母菌中,米诺环素几乎只对白假丝酵母菌在体外有抗菌活性。     

Rationally Designed Transmembrane Peptide Mimics of the Multidrug Transporter Protein Cdr1 Act as Antagonists to Selectively Block Drug Efflux and Chemosensitize Azole-resistant Clinical Isolates of Candida albicans

Drug-resistant pathogenic fungi use several families of membrane-embedded transporters to efflux antifungal drugs from the cells. The efflux pump Cdr1 (Candida drug resistance 1) belongs to the ATP-binding cassette (ABC) superfamily of transporters. Cdr1 is one of the most predominant mechanisms of multidrug resistance in azole-resistant (AR) clinical isolates of Candida albicans. Blocking drug efflux represents an attractive approach to combat the multidrug resistance of this opportunistic human pathogen. In this study, we rationally designed and synthesized transmembrane peptide mimics (TMPMs) of Cdr1 protein (Cdr1p) that correspond to each of the 12 transmembrane helices (TMHs) of the two transmembrane domains of the protein to target the primary structure of the Cdr1p. Several FITC-tagged TMPMs specifically bound to Cdr1p and blocked the efflux of entrapped fluorescent dyes from the AR (Gu5) isolate. These TMPMs did not affect the efflux of entrapped fluorescent dye from cells expressing the Cdr1p homologue Cdr2p or from cells expressing a non-ABC transporter Mdr1p. Notably, the time correlation of single photon counting fluorescence measurements confirmed the specific interaction of FITC-tagged TMPMs with their respective TMH. By using mutant variants of Cdr1p, we show that these TMPM antagonists contain the structural information necessary to target their respective TMHs of Cdr1p and specific binding sites that mediate the interactions between the mimics and its respective helix. Additionally, TMPMs that were devoid of any demonstrable hemolytic, cytotoxic, and antifungal activities chemosensitize AR clinical isolates and demonstrate synergy with drugs that further improved the therapeutic potential of fluconazole in vivo.     

Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages

Human serum, transferrin, and apotransferrin are known to profoundly inhibit the growth of Candida albicans by iron deprivation. On the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients. We tested the efficacy of fluconazole and the previously demonstrated synergy of fluconazole and effector cells against C. albicans under iron overload conditions where efficacy might be diminished. We confirm that exogenous iron completely reversed the inhibitory effect of human serum and report that the efficacy of fluconazole against C. albicans was not significantly compromised in a 24 h assay system. Although exogenous iron inhibited fungistatic activity of monocyte-derived macrophages, it did not interfere with the synergistic candidacidal activity of fluconazole and monocyte-derived macrophages. In 72 h assays, where fluconazole had candidacidal activity, exogenous iron did not compromise efficacy of fluconazole, and fluconazole activity was often increased. These in vitro results suggest that effectiveness of fluconazole therapy would not be compromised in iron overload situations in vivo. This revised version was published online in August 2006 with corrections to the Cover Date.     

Potential of plant oils as inhibitors of Candida albicans growth

Minimum inhibitory concentrations (MICs) and minimum fungicidal concentrations (MFCs) were determined for 38 oils of plant origin against Candida albicans. Four strains including one standard strain were used in this study. The antifungal agents, Fluconazole and Amphotericin B were used as positive controls. The standard strain (ATCC10231) used in this study was found to be highly resistant to Fluconazole: 3000 microg ml(-1) of Fluconazole was required to inhibit the growth of this strain partially, and complete inhibition could not be achieved. Other Candida strains were sensitive to 5 microg ml(-1) of Fluconazole. All the strains used were sensitive to Amphotericin B. Of the 38 oils tested, 23 were found effective and fifteen were ineffective. Based on their MFCs, effective oils were categorized into three categories. Seven oils, which exerted fungicidal effect at less than 0.15% concentration of oils, were grouped into the most effective class. The oils exhibiting MFCs in the range of 0.16-1.5% concentration were considered moderately effective. Nine oils, which required more than 1.5% concentration, were regarded as less effective. The Fluconazole-resistant strain (MTCC 227) was sensitive to at least 23 of the plant oils. Results of this study indicate that oils of plant origin may find use as potential anti-Candida agents.